140 related articles for article (PubMed ID: 25116415)
1. A time course-dependent metastatic gene expression signature predicts outcome in human metastatic melanomas.
Chen R; Zhang G; Zhou Y; Li N; Lin J
Diagn Pathol; 2014 Aug; 9():155. PubMed ID: 25116415
[TBL] [Abstract][Full Text] [Related]
2. Melanoma long non-coding RNA signature predicts prognostic survival and directs clinical risk-specific treatments.
Chen X; Guo W; Xu XJ; Su F; Wang Y; Zhang Y; Wang Q; Zhu L
J Dermatol Sci; 2017 Mar; 85(3):226-234. PubMed ID: 27955882
[TBL] [Abstract][Full Text] [Related]
3. Gene expression profiling of primary cutaneous melanoma and clinical outcome.
Winnepenninckx V; Lazar V; Michiels S; Dessen P; Stas M; Alonso SR; Avril MF; Ortiz Romero PL; Robert T; Balacescu O; Eggermont AM; Lenoir G; Sarasin A; Tursz T; van den Oord JJ; Spatz A;
J Natl Cancer Inst; 2006 Apr; 98(7):472-82. PubMed ID: 16595783
[TBL] [Abstract][Full Text] [Related]
4. Predicting the clinical outcome of melanoma using an immune-related gene pairs signature.
Meng L; He X; Zhang X; Zhang X; Wei Y; Wu B; Li W; Li J; Xiao Y
PLoS One; 2020; 15(10):e0240331. PubMed ID: 33031392
[TBL] [Abstract][Full Text] [Related]
5. The Identification and Validation of a Robust Immune-Associated Gene Signature in Cutaneous Melanoma.
Song LB; Luan JC; Zhang QJ; Chen L; Wang HY; Cao XC; Song NH; Lu Y
J Immunol Res; 2021; 2021():6686284. PubMed ID: 33688507
[TBL] [Abstract][Full Text] [Related]
6. A miRNA-Based Signature Detected in Primary Melanoma Tissue Predicts Development of Brain Metastasis.
Hanniford D; Zhong J; Koetz L; Gaziel-Sovran A; Lackaye DJ; Shang S; Pavlick A; Shapiro R; Berman R; Darvishian F; Shao Y; Osman I; Hernando E
Clin Cancer Res; 2015 Nov; 21(21):4903-12. PubMed ID: 26089374
[TBL] [Abstract][Full Text] [Related]
7. A Comprehensive Prognostic and Immunological Analysis of a Six-Gene Signature Associated With Glycolysis and Immune Response in Uveal Melanoma.
Liu J; Lu J; Li W
Front Immunol; 2021; 12():738068. PubMed ID: 34630418
[TBL] [Abstract][Full Text] [Related]
8. Transcriptomic Analysis Reveals Prognostic Molecular Signatures of Stage I Melanoma.
Thakur R; Laye JP; Lauss M; Diaz JMS; O'Shea SJ; Poźniak J; Filia A; Harland M; Gascoyne J; Randerson-Moor JA; Chan M; Mell T; Jönsson G; Bishop DT; Newton-Bishop J; Barrett JH; Nsengimana J
Clin Cancer Res; 2019 Dec; 25(24):7424-7435. PubMed ID: 31515461
[TBL] [Abstract][Full Text] [Related]
9. A Novel Autophagy-Related lncRNA Gene Signature to Improve the Prognosis of Patients with Melanoma.
Ding Y; Li T; Li M; Tayier T; Zhang M; Chen L; Feng S
Biomed Res Int; 2021; 2021():8848227. PubMed ID: 34250091
[TBL] [Abstract][Full Text] [Related]
10. Development of a prognostic genetic signature to predict the metastatic risk associated with cutaneous melanoma.
Gerami P; Cook RW; Wilkinson J; Russell MC; Dhillon N; Amaria RN; Gonzalez R; Lyle S; Johnson CE; Oelschlager KM; Jackson GL; Greisinger AJ; Maetzold D; Delman KA; Lawson DH; Stone JF
Clin Cancer Res; 2015 Jan; 21(1):175-83. PubMed ID: 25564571
[TBL] [Abstract][Full Text] [Related]
11. A novel immune checkpoint-related seven-gene signature for predicting prognosis and immunotherapy response in melanoma.
Tian M; Yang J; Han J; He J; Liao W
Int Immunopharmacol; 2020 Oct; 87():106821. PubMed ID: 32731180
[TBL] [Abstract][Full Text] [Related]
12. Loss of tumor suppressors KAI1 and p27 identifies a unique subgroup of primary melanoma patients with poor prognosis.
Zhang G; Cheng Y; Chen G; Tang Y; Ardekani G; Rotte A; Martinka M; McElwee K; Xu X; Wang Q; Zhou Y
Oncotarget; 2015 Sep; 6(26):23026-35. PubMed ID: 26246476
[TBL] [Abstract][Full Text] [Related]
13. A nine-gene signature predicting clinical outcome in cutaneous melanoma.
Brunner G; Reitz M; Heinecke A; Lippold A; Berking C; Suter L; Atzpodien J
J Cancer Res Clin Oncol; 2013 Feb; 139(2):249-58. PubMed ID: 23052696
[TBL] [Abstract][Full Text] [Related]
14. Is nonmetastatic cutaneous melanoma predictable through genomic biomarkers?
Branca M; Orso S; Molinari RC; Xu H; Guerrier S; Zhang Y; Mili N
Melanoma Res; 2018 Feb; 28(1):21-29. PubMed ID: 29194095
[TBL] [Abstract][Full Text] [Related]
15. Melanoma MicroRNA signature predicts post-recurrence survival.
Segura MF; Belitskaya-Lévy I; Rose AE; Zakrzewski J; Gaziel A; Hanniford D; Darvishian F; Berman RS; Shapiro RL; Pavlick AC; Osman I; Hernando E
Clin Cancer Res; 2010 Mar; 16(5):1577-86. PubMed ID: 20179230
[TBL] [Abstract][Full Text] [Related]
16. Metastatic lesions with and without interleukin-18-dependent genes in advanced-stage melanoma patients.
Crende O; Sabatino M; Valcárcel M; Carrascal T; Riestra P; López-Guerrero JA; Nagore E; Mandruzzato S; Wang E; Marincola FM; Vidal-Vanaclocha F
Am J Pathol; 2013 Jul; 183(1):69-82. PubMed ID: 23707237
[TBL] [Abstract][Full Text] [Related]
17. Construction of a novel mRNA-signature prediction model for prognosis of bladder cancer based on a statistical analysis.
Li J; Cao J; Li P; Yao Z; Deng R; Ying L; Tian J
BMC Cancer; 2021 Jul; 21(1):858. PubMed ID: 34315402
[TBL] [Abstract][Full Text] [Related]
18. Construction and optimization of gene expression signatures for prediction of survival in two-arm clinical trials.
Theilhaber J; Chiron M; Dreymann J; Bergstrom D; Pollard J
BMC Bioinformatics; 2020 Jul; 21(1):333. PubMed ID: 32711453
[TBL] [Abstract][Full Text] [Related]
19. Gene signature of the metastatic potential of cutaneous melanoma: too much for too little?
Tímár J; Gyorffy B; Rásó E
Clin Exp Metastasis; 2010 Aug; 27(6):371-87. PubMed ID: 20177751
[TBL] [Abstract][Full Text] [Related]
20. A seven-marker signature and clinical outcome in malignant melanoma: a large-scale tissue-microarray study with two independent patient cohorts.
Meyer S; Fuchs TJ; Bosserhoff AK; Hofstädter F; Pauer A; Roth V; Buhmann JM; Moll I; Anagnostou N; Brandner JM; Ikenberg K; Moch H; Landthaler M; Vogt T; Wild PJ
PLoS One; 2012; 7(6):e38222. PubMed ID: 22685558
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]